Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.
Moleculin Biotech announced that interim data from its pivotal Phase 2/3 trial (MB-108) of Annamycin for relapsed or refractory AML will be presented at the 2026 ASH Annual Meeting. The data showed complete remission rates of 43% and 36% in the treatment arms compared to 12% for placebo, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended the study continue without amendment.
Moleculin Biotech has completed and closed enrollment for Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (R/R AML). The company enrolled 89 subjects and remains on track for a comprehensive data readout in the first quarter of 2027. The final Part A dataset is expected to provide efficacy insights across both 'fit' and 'unfit' patient populations, with an estimated 50/50 split between those previously treated with intensive chemotherapy versus venetoclax-based regimens.
Moleculin Biotech announced the peer-reviewed publication of a pooled cardiac safety analysis of its drug candidate Annamycin in Frontiers in Cardiovascular Medicine. The analysis of 90 patients across five clinical trials found no clinical or subclinical evidence of cardiotoxicity, even at cumulative doses exceeding traditional anthracycline limits.
Counterparty
Cleveland Clinic
“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program. For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Moleculin Biotech announced new preclinical data for its lead drug candidate, Annamycin, showing that its antitumor activity in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity. The findings, presented at the AACR Conference on Pancreatic Cancer, suggest the drug may turn immunologically 'cold' tumors 'hot,' potentially enabling new combination therapy approaches.
Moleculin Biotech raised $0.48 million in gross proceeds through the issuance of 888,400 shares under its at-the-market (ATM) offering program in September 2026. The issuance triggered an anti-dilution provision in the company's Series I Warrants, reducing their exercise price from $0.75 to $0.51 per share.
Moleculin Biotech received a Staff Determination Letter from Nasdaq notifying the company that its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days. Because the company already performed a reverse stock split within the last year, it is ineligible for the standard 180-day grace period and faces immediate delisting unless it successfully appeals to the Nasdaq Hearings Panel.
Moleculin Biotech announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the AACR Conference on Pancreatic Cancer. The presentations will cover the drug's organotropism, its mechanism for targeting topoisomerase II, and its ability to stimulate CD8+ T cell cytotoxicity in pancreatic tumors. These findings support the company's broader development of Annamycin beyond its lead indication in acute myeloid leukemia (AML).